VOORHEES, N.J.—The medical part molder Comar will expand its manufacturing capacity on the East Coast and the West Coast with the construction of two new facilities, the company announced recently.
Comar (www.comar.com), a supplier of plastic healthcare packaging, devices, and components, reported in June that it would expand its Buena plant operations by building a new 159,000-square-foot facility offsite in Vineland, New Jersey. The announcement followed an earlier report by the company that it is building a custom, 230,000-square-foot facility in Rancho Cucamonga, California.
The Vineland facility, only a 20-minute drive from the current facility, will be ISO 13485 certified, cGMP compliant, and FDA registered. It will house injection molding, assembly, and finishing machines, with additional capacity to support long-term growth. The expansion is scheduled to be completed by March 2021, the company said in a release.
“This investment builds on our new West Coast facility—Rancho 2.0—and represents another exciting milestone for our organization,” said Comar CEO Mike Ruggieri, in a statement. “Our Buena plant has provided the engine for much of our growth over the decades. This next critical step of adding footprint, infrastructure, and capacity will ensure that we continue to delight our customers and drive our growth moving forward.”
Comar’s New Jersey expansion effort will create additional space for injection molding, assembly, and finishing operations, while also increasing the firm’s warehouse and storage space. The new facility will feature an improved cGMP environment and quality lab. It will also include enhancements to the layout—with more dedicated product cells to drive speed-to-market—and to the design. The goal is to enable better efficiency, safety, and employee experience, the company said.
“In addition to better serving our customers by bringing additional production capacity, the expansion in Southern New Jersey will create a better experience for our employees, who are central to delighting our customers,” said Linda Kershner, Buena plant manager at Comar, in the release. “I am extremely excited about both our current Buena and new Vineland facilities. The new Vineland location allows us to create a best-in-class cGMP compliant work environment right from the start and, at the same time, gives us the opportunity to refresh and optimize our Buena site.”
Like the Vineland facility, Comar’s custom facility in Rancho Cucamonga, California, will be ISO 13485 certified, cGMP compliant, and FDA registered. It will house dedicated injection blow molding, injection stretch blow molding, and injection molding cells. Approximately 26,000 square feet of the facility will have ISO Class 8 injection molding and assembly cleanrooms, with room to expand.
The facility will support manufacturing of complex finished medical devices and sub-assemblies incorporating injection molding, blow molding, high speed assembly, testing, and finished device pack-out. With a full-service mold prototyping lab and dedicated mold sampling and development equipment, the facility will enable Comar to rapidly bring customers from ideation to design, prototype, and full production, the company said.
“This transformational investment is an exciting milestone for our organization,” Ruggieri said. “We have an opportunity to create a purpose-built facility that will enhance the employee experience, delight our customers, and provide a path for significant continued growth. This new facility will provide best-in-class medical device production areas and significant additional capacity to grow with our customers across product lines and market segments.”
Comar will consolidate current employees, equipment, and operations from its existing Rancho Cucamonga and Garden Grove plants into the new facility.
“Combining our team into a single campus creates the opportunity for employees to strengthen and grow their expertise to support our customer’s needs,” said Pete Scharber, vice president, direct sales. “We are excited to amplify the Comar value proposition for our medical customers and create additional avenues to collaborate, reduce costs, mitigate risk, and further partner in their success as a single source of supply.”